Roth Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $38
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Roth Capital analyst Salveen Richter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $44 to $38.
Roth Capital analyst Salveen Richter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $44 to $38.